Stocktoria
PUMA BIOTECHNOLOGY, INC. PBYI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-03-21
PUMA BIOTECHNOLOGY, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.5% |
| Net margin | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% |
| FCF margin | 18.3% | 16.9% | 11.4% | -6.9% | 8.2% |
| Return on assets | 14.4% | 14.2% | 9.4% | 0.0% | -12.9% |
| Return on equity | 23.9% | 32.9% | 40.4% | 0.0% | 1190.8% |
| Debt / equity | 0.17× | 0.74× | 1.91× | 4.72× | -41.70× |
| Current ratio | 2.00 | 1.54 | 1.57 | 1.73 | 1.28 |
| Revenue growth | -0.9% | -2.2% | 3.3% | -9.9% | 12.5% |
Source: SEC EDGAR filings · CIK 0001401667 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.